A Heidenreich


Affiliation: University of Cologne
Country: Germany


  1. Heidenreich A. [Educational research in urology : Innovations for improving training]. Urologe A. 2019;: pubmed publisher
  2. Heidenreich A, Gillessen S, Heinrich D, Keizman D, O Sullivan J, Carles J, et al. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC Cancer. 2019;19:12 pubmed publisher
    ..The study was registered with ClinicalTrials.gov , number NCT01618370 on June 13, 2012 and the European Union Clinical Trials Register, EudraCT number 2012-000075-16 on April 4, 2012. ..
  3. Hakenberg O, Perez Gracia J, Castellano D, Demkow T, Ali T, Caffo O, et al. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;107:186-195 pubmed publisher
    ..043). Olaratumab + M/P had an acceptable safety profile but did not improve the efficacy of M/P chemotherapy. Further study with selected patient populations and earlier in the disease course might be considered. ..
  4. Paffenholz P, Grein K, Heidegger I, Nestler T, Grabbert M, Salem J, et al. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol. 2018;: pubmed publisher
    ..As a result, monitoring of cancer patients at risk as well as the improvement of patients' awareness of a thromboembolic event should thus be the main goal of their treating physicians. ..
  5. Paffenholz P, Pfister D, Matveev V, Heidenreich A. Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature. Urol Oncol. 2018;36:529.e23-529.e30 pubmed publisher
    ..Due to its complexity and potential adjunctive surgery, the treatment should be performed in tertiary referral centers only. ..
  6. Heidenreich A. [Limits of surgery in uro-oncology]. Urologe A. 2018;57:1058-1068 pubmed publisher
    ..In addition, specific clinical scenarios are discussed with regard to surgery limits in cancer of the kidney, the prostate and the testis. ..
  7. Paffenholz P, Held L, Loosen S, Pfister D, Heidenreich A. Testis Sparing Surgery for Benign Testicular Masses: Diagnostics and Therapeutic Approaches. J Urol. 2018;200:353-360 pubmed publisher
    ..8 cm3 and there are hormone disorders or normal tumor markers. Immediate orchiectomy should be avoided, favoring testis sparing surgery. ..
  8. Paffenholz P, Pfister D, Heidenreich A. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours]. Urologe A. 2016;55:632-40 pubmed publisher
    ..Even the involvement of vascular vertebral structures does not constitute a contraindication for complete resection. ..
  9. Heidenreich A, Böhmer D. [Multimodal therapy of locally advanced prostate cancer]. Urologe A. 2016;55:333-44 pubmed publisher
    ..Combination with neoadjuvant or adjuvant chemotherapy and new androgen receptor pathway inhibitors might also be possible. This article summarizes the current treatment strategies for LAPCA. ..

More Information


  1. Haidl F, Pfister D, Semrau R, Heidenreich A. [Second neoplasms after percutaneous radiotherapy]. Urologe A. 2017;56:342-350 pubmed publisher
    ..Symptoms or findings of microhematuria need to be examined thoroughly after radiation therapy to identify bladder cancer quite early. ..
  2. Heidenreich A, Paffenholz P, Haidl F, Pfister D. [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]. Urologe A. 2017;56:627-636 pubmed publisher
    ..Due to the complexity and the lower rate of significant morbidity and mortality, these procedures should be done at tertiary referral centers. ..
  3. Heidenreich A, Chowdhury S, Klotz L, Siemens D, Villers A, Ivanescu C, et al. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Eur Urol. 2017;71:534-542 pubmed publisher
    ..This likely relates to previously reported lower rates of symptomatic disease progression. ..
  4. Heidenreich A, Thüer D, Polyakov S. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol. 2008;53:260-72 pubmed
    ..PC-RPLND requires a complex surgical approach and should be performed in experienced, tertiary referral centres only. ..
  5. Paffenholz P, Heidegger I, Kuhr K, Loosen S, Pfister D, Heidenreich A. Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival. Clin Genitourin Cancer. 2017;: pubmed publisher
    ..The purpose of the present study was to evaluate the compliance patterns in diagnosis and therapy and their potential effects on patient outcomes with respect to the guidelines of the European Association of Urology...
  6. Pircher A, Wolf D, Heidenreich A, Hilbe W, Pichler R, Heidegger I. Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. Int J Mol Sci. 2017;18: pubmed publisher
    ..Particular attention will also be paid to potential novel treatment-related adverse events induced by combination treatment. ..
  7. Paffenholz P, Salem J, Borgmann H, Nestler T, Pfister D, Ruf C, et al. Testicular Cancer on the Web-an Appropriate Source of Patient Information in Concordance with the European Association of Urology Guidelines?. J Cancer Educ. 2018;33:1314-1322 pubmed publisher
    ..However, improvement regarding readability and completeness of the given information is needed. Nevertheless, highly selected websites on testicular cancer can serve as an appropriate source of patient information. ..
  8. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev V, Schmid H, et al. [EAU guidelines on prostate cancer]. Actas Urol Esp. 2009;33:113-26 pubmed
    ..To present a summary of the 2007 version of the European Association of Urology (EAU) guidelines on prostate cancer (PCa)...